Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance:
Advanced therapies Why promoter design is no longer just an expression checkbox, it’s the key…
27 July 2026
Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the protein driving up to 97% of ALS cases.
VTx-002 aims to provide a durable therapeutic effect by delivering an antibody gene via an AAV5.2 vector, turning the patient’s cells into continuous drug factories. This continuous production is vital for treating progressive diseases like ALS.
The persistent, high-level expression of the VTx-002 antibody within the target cells is powered by a bespoke promoter for which Annogen’s proprietary SuRE™ platform formed the basis for discovery, ensuring essential, long-lasting expression for the genetic payload.
The PIONEER-ALS trial will evaluate the safety and tolerability of VTx-002, which represents a crucial step toward addressing the urgent, unmet medical need in ALS.
Founded in 2017, Annogen is a leader in tailored gene expression engineering, focused on making advanced therapies safer and more effective. Through our proprietary SuRE™ platform, we characterize millions of cis-regulatory sequences both in vivo and in vitro, enabling the development of novel, patentable promoters and gain-of-function gene-editing strategies. We offer off-the-shelf promoters that are extensively validated—including in clinical-stage therapies—as well as bespoke gene expression engineering programs tailored to specific applications. Together, these capabilities support innovation across cell and gene therapy, biopharmaceutical manufacturing, and agricultural trait development.
